Older Adults Called 'Evidence Free' as New Drugs Skip Key Demographic

Gerontologist Sam Cradduck stated that older adults are frequently excluded from clinical trials, a practice that leaves the demographic without adequate safety data for new medications. She described the situation as leaving older patients walking blind because drug metabolism differs significantly between older and younger bodies.

Cradduck explained that the Food and Drug Administration cannot approve new medicines without clinical trial data. She noted that without older participants, researchers lack the necessary information to determine how drugs affect senior physiology. She addressed the common fear of being a guinea pig by stating that trials reaching this stage have been thoroughly tested repeatedly. She emphasized that adverse effects exist in all prescribed treatments, making informed participation essential.

Aging expert Amy O'Rourke highlighted that older adults are often termed evidence free because they are systematically left out of research. She observed that patients who join local clinical trial groups often report feeling hopeful and connected to their community. She cited a local group where social workers provided support networks and access to community resources, which she described as a huge value for older participants.

Dr. Rhea Rogers, a board certified physician, advised patients to shift their focus from whether a trial will help them personally to what scientific question the study is designed to answer. She stated that many individuals incorrectly view clinical trials as a last resort option when other treatments have failed. Rogers argued that the primary benefit of participation is immediate access to tomorrow's medicines, devices, and therapies that will not be available to the general public for years.

Rogers identified ClinicalTrials.gov, physician referrals, and academic centers as primary locations for finding studies. She noted that many trials cover costs such as gas money, and some compensate participants financially. O'Rourke added that the National Institutes of Health maintains a list of clinical trials and indicates which studies offer financial compensation.

Participants must understand the mechanics of randomization before enrolling. O'Rourke stated that a participant might receive a placebo or the active drug, and the expectation should not be guaranteed improvement. She advised that knowing this going in helps manage expectations regarding the treatment outcome. The experts agreed that proactive participation allows older adults to access cutting edge treatments and contribute to safer future medication approvals.